Associated Genetic Biomarkers

Overview

Gene Location [1]
11p13
Pathway
Beta-Catenin/WNT signaling
Gene
WT1

WT1 Mutation is present in 1.15% of AACR GENIE cases, with lung adenocarcinoma, acute myeloid leukemia, colon adenocarcinoma, breast invasive ductal carcinoma, and cutaneous melanoma having the greatest prevalence [4].

Top Disease Cases with WT1 Mutation

Significance of WT1 Mutation in Diseases

Acute Myeloid Leukemia +

Myeloid Neoplasm +

Acute Lymphoblastic Leukemia +

Non-Hodgkin Lymphoma +

Acute Biphenotypic Leukemia +

Acute Erythroid Leukemia +

Acute Megakaryoblastic Leukemia +

Acute Undifferentiated Leukemia +

Chronic Myeloid Leukemia +

Hodgkin Lymphoma +

Juvenile Myelomonocytic Leukemia +

Myelodysplastic Syndrome With Excess Blasts-2 +

Myelodysplastic Syndromes +

Myeloid Sarcoma +

Natural Killer Cell Lymphoblastic Leukemia/Lymphoma +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.

Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.

4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

5. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.